会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 14. 发明授权
    • Aerodynamically light particles for pulmonary drug delivery
    • 用于肺部药物递送的空气动力学轻微颗粒
    • US06977087B2
    • 2005-12-20
    • US10090418
    • 2002-03-01
    • David A. EdwardsGiovannia CaponettiJeffrey S. HrkachNoah LotanJustin HanesAbdell Aziz Ben-JebriaRobert S. Langer
    • David A. EdwardsGiovannia CaponettiJeffrey S. HrkachNoah LotanJustin HanesAbdell Aziz Ben-JebriaRobert S. Langer
    • A61K9/00A61K9/14A61K9/16A61K31/56A61K31/568A61K38/28
    • A61K9/0075A61K9/1647A61K31/56A61K31/568A61K38/28
    • Improved aerodynamically light particles for delivery to the pulmonary system, and methods for their preparation and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of a biodegradable material and have a tap density less than 0.4 g/cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated herein and at least on poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic or diagnostic agent to the alveolar region of the lung. The aerodynamically light particles optionally can incorporate a therapeutic or diagnostic agent, and may be effectively aerosolized for administration to the respiratory tract to permit systemic or local delivery of a wide variety of incorporated agents.
    • 提供用于递送至肺系统的改善的空气动力学轻微颗粒,以及其制备和给药方法。 在优选的实施方案中,空气动力学轻微颗粒由可生物降解的材料制成,并且振实密度小于0.4g / cm 3,质量平均直径在5μm和30μm之间。 颗粒可以由可生物降解的材料如可生物降解的聚合物形成。 例如,颗粒可以由官能化的聚酯接枝共聚物形成,所述官能化聚酯接枝共聚物由具有至少一个引入本文的氨基酸基团和至少在从氨基酸延伸的聚(氨基酸)侧链上的直链α-羟基酸聚酯主链组成 集团在聚酯骨干。 在一个实施方案中,具有大平均直径(例如大于5μm)的空气动力学轻的颗粒可用于增强治疗或诊断剂递送至肺的肺泡区域。 空气动力学轻微颗粒任选地可以掺入治疗剂或诊断剂,并且可以有效地雾化用于给予呼吸道以允许各种并入药剂的全身或局部递送。
    • 18. 发明授权
    • Particles for treatment of pulmonary infection
    • 用于治疗肺部感染的颗粒
    • US08846607B2
    • 2014-09-30
    • US11720595
    • 2005-10-19
    • David A. EdwardsJennifer FiegelJean Sung
    • David A. EdwardsJennifer FiegelJean Sung
    • A61K9/14A61P31/06A61P11/00A61K38/12A61K9/00A61K9/16
    • A61K9/0075A61K9/1617A61K9/1694Y10S514/924
    • Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration. Optionally, the nanoparticles are coated, such as with a surfactant or protein coating. The formulation may be administered as a powder or administered as a solution or via an enteral or non-pulmonary parenteral route of administration. The formulation is preferably administered as a pulmonary formulation. In the preferred embodiment for treatment of TB, the vaccine is a BCG vaccine that is stable at room temperature, or is an antibiotic effective against TB, such as capreomycin or PA-824, loaded at a very high percentage into the microparticles or nanoparticles. In one embodiment, a patient is treated with formulations delivering both antibiotic and vaccine.
    • 已经开发了治疗或减少呼吸道感染传播的制剂,特别是慢性或耐药性感染,特别是结核病(TB),严重急性呼吸综合征(SARS),脑膜炎球菌性脑膜炎,呼吸道合胞病毒(RSV),流感和小痘 。 制剂包括纳米颗粒的微粒,纳米颗粒或骨料形式的药物或疫苗,以及任选的可以通过吸入递送的载体。 通过吸入器给药可以通过绕过胃和肝来避开与口服或可注射药物相关的问题,并将药物直接送入肺部。 在一个实施方案中,含有该试剂的颗粒是大的多孔气溶胶颗粒(LPPs)。 在另一个实施方案中,颗粒是纳米颗粒,其可以作为具有微米直径的多孔纳米颗粒聚集体施用,其在施用后分散到纳米颗粒中。 任选地,包覆纳米颗粒,例如用表面活性剂或蛋白质涂层。 制剂可以粉末形式施用或作为溶液给药或通过肠内或非肺部非肠道途径给药。 制剂优选作为肺制剂施用。 在用于治疗结核病的优选实施方案中,疫苗是在室温下稳定的BCG疫苗,或者是针对TB有效的抗生素,例如卷曲霉素或PA-824,其以非常高的百分比加载到微粒或纳米颗粒中。 在一个实施方案中,用递送抗生素和疫苗的制剂治疗患者。